Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
Title:
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
Author:
Forrest, Donna L. Trainor, Shannon Brinkman, Ryan R. Barnett, Michael J. Hogge, Donna E. Nevill, Thomas J. Shepherd, John D. Nantel, Stephen H. Toze, Cynthia L. Sutherland, Heather J. Song, Kevin W. Lavoie, Julye C. Power, Maryse M. Abou-Mourad, Yasser Smith, Clayton A.